Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Nexstim

Related articles:
2/28/2023 1:37:25 PM - Nexstim H2 2022: Slight miss – but long term profitability in sight - Redeye - Redeye provides a research update after Nexstim's H2 report, which came in slightly below our projections. As a result, we have made minor adjustments to our base case and provided our perspective on 2023.
2/9/2023 4:16:59 PM - Nexstim avnoteras från First North i Stockholm, behåller noteringen i Helsingfors - Medicinteknikbolaget Nextstims ansökan om avnotering från Nasdaq First North Growth Market i Stockholm har godkänts. Sista handelsdagen i Stockholm blir den 14 april. Det framgår av ett meddelande från börsoperatören Nasdaq.
10/24/2022 8:57:30 AM - Nexstim: Business & Clinical Update for Q3 - Redeye - Redeye reiterates its positive stance to Nexstim following last week’s Q3 update.
9/9/2022 5:17:55 AM - Nexstim: FDA Clearance for Partner Magnus Medical - Redeye - We give a short comment on the recent FDA clearance for Nexstim’s partner Magnus Medical.
8/19/2022 7:04:30 AM - Nexstim: H1 2022 – Some good, but near-term uncertainties remain - Redeye - Redeye raises its full-year sales estimates for 2022E from EUR 7.6m to EUR 10.2m but lower our 2023-2024 estimates by 7-20% following the report and licensing agreement with Magnus Medical. We continue to see good prospects in Nexstim but argue that the slowing growth in the NBT segment and upcoming licensing period add some uncertainty to the case for growth in the upcoming years. We slightly lower our base case to SEK 62.5 per share.
3/1/2022 11:10:20 AM - Nexstim H2’21 Report: Follow up Comment - Redeye - Redeye is encouraged by the continued momentum in Nexstim and path towards profitability, although with a somewhat new focus following the recent licensing agreement. We slightly increase our base case to SEK 67,5 per share but could adjust further as we learn more about the plans for collaborator Magnus Medical.
2/28/2022 8:43:39 AM - Nexstim H2’21 Report: Initial Take - Redeye - We given an initial take on Nexstim’s H2 report, that further proved Nexstim’s capability to turn the company profitable.
2/15/2022 9:00:13 AM - Nexstim: A Change of Focus - Redeye - Redeye is cautiously optimistic to yesterday’s licensing agreement between Nexstim and Magnus Medical and gives an initial take.
12/16/2021 9:04:08 AM - Nexstim: Results from accelerated TMS Pilot Study in Chronic Pain - Redeye - We give a short comment on the results from Nexstim’s pilot study in chronic pain.
12/15/2021 8:07:34 AM - Nexstim: Doing The Right Things - Redeye - Since our initiation of coverage, Nexstim has continued to deliver solid and higher-than-expected growth in its key segments of diagnostics and therapeutics. We take a more positive stance on Nexstim and increase our valuation to SEK 65 (60) – representing upside of roughly 40 percent. We slightly lift our near-term growth expectations for the key diagnostics and depression therapy segments (NBS and NBT), assigning a CAGR of 27% in the upcoming five years, as well as our estimation of profitability.
10/22/2021 1:49:51 PM - Nexstim: Launches Combined System in the US - Redeye - Redeye has a positive take on the news that Nexstim has launched a combined NBS/NBT system in the US. We give a short comment.
8/13/2021 11:35:58 AM - Nexstim H1 2021: Our initial take - Redeye - We give our take on today’s H1 report from Nexstim. We are overall pleased with the developments in Nexstim so far this year, as sales exceeded our estimates with significant growth across the board. At this point, we make some adjustments to our full year estimates and increase our base case to SEK 60 (55).
7/2/2021 8:28:51 AM - Nexstim: Minor Delay in Chronic Neuropathic Pain Pilot Study - Redeye - Nexstim announced today that its ongoing pilot study using an accelerated TMS protocol to treat chronic neuropathic pain has been slightly delayed due to the pandemic. The company will continue to recruit patients during Q3 (previously H1). We consider the delay a minor issue, also as we do not value the accelerated treatment protocol at this point, and thus do not make any changes to our valuation of the company.
5/17/2021 8:59:29 AM - Nexstim: Adjusting Valuation for Reversed Split - Redeye - We adjust our fair value range following Nexstim’s decision to do a reverse split (100-to-1).